A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
← catalyst calendarSponsored by Verastem, Inc. (industry) · VSTM — their whole pipeline →. With Japanese Gynecologic Oncology Group.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
16actual
Sites
5
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-30 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Low Grade Serous Ovarian Cancer
- Ovarian Cancer
Intervention
- Drug: Avutometinib (VS-6766) + Defactinib (VS-6063)
Primary outcome
what the primary-completion date above is the date OFConfirmed overall response rate (ORR; partial response [PR] + complete response [CR]
measured From start of treatment to confirmation of response; 24 weeks
Permalink · VSTM's whole pipeline · Catalyst calendar · Every registered study · What changed